194 related articles for article (PubMed ID: 23110890)
1. Cabergoline therapy for macroprolactinoma during pregnancy: a case report.
Shahzad H; Sheikh A; Sheikh L
BMC Res Notes; 2012 Oct; 5():606. PubMed ID: 23110890
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
Sabuncu T; Arikan E; Tasan E; Hatemi H
Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
[TBL] [Abstract][Full Text] [Related]
3. Pregnancy and tumor outcomes in infertile women with macroprolactinoma on cabergoline therapy.
Rastogi A; Bhadada SK; Bhansali A
Gynecol Endocrinol; 2017 Apr; 33(4):270-273. PubMed ID: 27908214
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of a large macroprolactinoma with cabergoline during pregnancy.
Liu C; Tyrrell JB
Pituitary; 2001 Aug; 4(3):179-85. PubMed ID: 12138991
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of macroprolactinoma with cabergoline during pregnancy].
Forsbach-Sánchez G; Tamez-Pérez HE; Hernández-Herrera R; Bafidis-Lechuga B
Rev Med Inst Mex Seguro Soc; 2009; 47(3):307-10. PubMed ID: 20141661
[TBL] [Abstract][Full Text] [Related]
6. High dose cabergoline therapy for a resistant macroprolactinoma during pregnancy.
Banerjee A; Wynne K; Tan T; Hatfield EC; Martin NM; Williamson C; Meeran K
Clin Endocrinol (Oxf); 2009 May; 70(5):812-3. PubMed ID: 18803677
[No Abstract] [Full Text] [Related]
7. Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas.
Iyer P; Molitch ME
Endocr Pract; 2011; 17(3):e55-8. PubMed ID: 21324816
[TBL] [Abstract][Full Text] [Related]
8. Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis.
Hu J; Zheng X; Zhang W; Yang H
Pituitary; 2015 Oct; 18(5):745-51. PubMed ID: 25500765
[TBL] [Abstract][Full Text] [Related]
9. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas.
Ono M; Miki N; Amano K; Kawamata T; Seki T; Makino R; Takano K; Izumi S; Okada Y; Hori T
J Clin Endocrinol Metab; 2010 Jun; 95(6):2672-9. PubMed ID: 20357175
[TBL] [Abstract][Full Text] [Related]
10. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy.
Kharlip J; Salvatori R; Yenokyan G; Wand GS
J Clin Endocrinol Metab; 2009 Jul; 94(7):2428-36. PubMed ID: 19336508
[TBL] [Abstract][Full Text] [Related]
11. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
Verhelst J; Abs R; Maiter D; van den Bruel A; Vandeweghe M; Velkeniers B; Mockel J; Lamberigts G; Petrossians P; Coremans P; Mahler C; Stevenaert A; Verlooy J; Raftopoulos C; Beckers A
J Clin Endocrinol Metab; 1999 Jul; 84(7):2518-22. PubMed ID: 10404830
[TBL] [Abstract][Full Text] [Related]
12. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia.
Colao A; Sarno AD; Cappabianca P; Briganti F; Pivonello R; Somma CD; Faggiano A; Biondi B; Lombardi G
Eur J Endocrinol; 2003 Mar; 148(3):325-31. PubMed ID: 12611613
[TBL] [Abstract][Full Text] [Related]
13. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
[TBL] [Abstract][Full Text] [Related]
14. SHORT-TERM DECLINE IN PROLACTIN CONCENTRATIONS CAN PREDICT FUTURE PROLACTIN NORMALIZATION, TUMOR SHRINKAGE, AND TIME TO REMISSION IN MEN WITH MACROPROLACTINOMAS.
Tirosh A; Benbassat C; Shimon I
Endocr Pract; 2015 Nov; 21(11):1240-7. PubMed ID: 26247115
[TBL] [Abstract][Full Text] [Related]
15. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
[TBL] [Abstract][Full Text] [Related]
16. Late development of resistance to bromocriptine in a patient with macroprolactinoma.
Delgrange E; Crabbé J; Donckier J
Horm Res; 1998; 49(5):250-3. PubMed ID: 9568811
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacologic cure of a pituitary macroprolactinoma].
Hurtado Amador R; Ayala AR
Ginecol Obstet Mex; 2003 Oct; 71():522-6. PubMed ID: 15002692
[TBL] [Abstract][Full Text] [Related]
18. Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women.
Lebbe M; Hubinont C; Bernard P; Maiter D
Clin Endocrinol (Oxf); 2010 Aug; 73(2):236-42. PubMed ID: 20455894
[TBL] [Abstract][Full Text] [Related]
19. Evaluaton of therapy with cabergoline in men with macroprolactinoa.
Andrysiak-Mamos E; Kaźmierczyk-Puchalska A; Zochowska E; Sowińska-Przepiera E; Sagan L; Kojder I; Syrenicz A
Pomeranian J Life Sci; 2015; 61(3):263-9. PubMed ID: 27344867
[TBL] [Abstract][Full Text] [Related]
20. Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma.
Cannavò S; Curtò L; Squadrito S; Almoto B; Vieni A; Trimarchi F
J Endocrinol Invest; 1999 May; 22(5):354-9. PubMed ID: 10401709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
